$376.35
Up 0.19% · Snapshot Sep 16, 2026
Market cap
$203.47B
Market cap $203.47B
Adjust assumptions
Adjust the usable peer mix to see how each valuation multiple moves the blended fair value.
Peer-implied fair value
$2,033.35
Blended value per share under the current mix.
Current price
$376.35
Sep 16, 2026
Peer gap
+440.3%
Peers imply 440.3% upside
Weighting mixer
Value contribution
6 peers →Price / Sales
$1.10T
Price / Sales
$1.10T
Equal-weight baseline
Premium 0.0%The simple average of every usable peer method, before your weighting adjustments.
Baseline equity value
$1.10T
Baseline / share
$2,033.35
Relative valuation prices this company against what the market already pays for its peers. For a cash-flow view that does not inherit peer sentiment, open the intrinsic model.
Spreadsheet data
Audit the saved peer set and the method inputs behind the blended fair value.
The saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market cap | Enterprise value | Revenue | EBITDA |
|---|
| Net income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
REGN REGENERON PHARMACEUTICALS, INC. FY ended Dec 31, 2025 | — | — | — | $14.34B | $5.62B | $4.50B | — | — | — |
BIIB BIOGEN INC. FY ended Feb 04, 2026 | — | — | — | $9.89B | $2.60B | $1.29B | — | — | — |
VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | — | — | — | $12.00B | $4.88B | $3.95B | — | — | — |
GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | — | — | — | $29.44B | $13.51B | $8.51B | — | — | — |
MRNA Moderna, Inc. FY ended Feb 13, 2026 | $145.65 | $58.15B | — | $1.94B | -$2.76B | -$2.82B | -20.06x | 29.91x | — |
LLY ELI LILLY & Co FY ended Feb 09, 2026 | — | — | — | $65.18B | $28.02B | $20.64B | — | — | — |
REGN
REGENERON PHARMACEUTICALS, INC.
—
—
—
$14.34B
$5.62B
—
—
—
Cap —EV —Rev $14.34BEBITDA $5.62BP/E —P/S —EV/EBITDA —
BIIB
BIOGEN INC.
—
—
—
$9.89B
$2.60B
—
—
—
Cap —EV —Rev $9.89BEBITDA $2.60BP/E —P/S —EV/EBITDA —
VRTX
VERTEX PHARMACEUTICALS INC / MA
—
—
—
$12.00B
$4.88B
—
—
—
Cap —EV —Rev $12.00BEBITDA $4.88BP/E —P/S —EV/EBITDA —
GILD
GILEAD SCIENCES, INC.
—
—
—
$29.44B
$13.51B
—
—
—
Cap —EV —Rev $29.44BEBITDA $13.51BP/E —P/S —EV/EBITDA —
MRNA
Moderna, Inc.
$145.65
$58.15B
—
$1.94B
-$2.76B
-20.06x
29.91x
—
Cap $58.15BEV —Rev $1.94BEBITDA -$2.76BP/E -20.06xP/S 29.91xEV/EBITDA —
LLY
ELI LILLY & Co
—
—
—
$65.18B
$28.02B
—
—
—
Cap —EV —Rev $65.18BEBITDA $28.02BP/E —P/S —EV/EBITDA —
Which peer averages feed the weighted fair value, and which methods are excluded.
| Method | Type | Avg. multiple | Coverage | Implied equity value | Fair value / share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/6 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 29.91x | 1/6 | $1.10T | $2,033.35 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -20.06x | 1/6 | -$154.70B | — | Peer averages are not economically meaningful for this method. |
EV / EBITDA
EV · Enterprise Multiple
Avg. multiple
—
Coverage
0/6
Implied equity value
—
Fair value / share
—
No saved peers have usable coverage for this method.
Price / Sales
PS · Equity Multiple
Avg. multiple
29.91x
Coverage
1/6
Implied equity value
$1.10T
Fair value / share
$2,033.35
Included in the active peer mix.
Price / Earnings
PE · Equity Multiple
Avg. multiple
-20.06x
Coverage
1/6
Implied equity value
-$154.70B
Fair value / share
—
Peer averages are not economically meaningful for this method.
